Trade

with

Aastrom Biosciences Inc
(NASDAQ: ASTM)
AdChoices
2.93
+0.02
+0.72%
After Hours :
-
-
-

Open

2.92

Previous Close

2.91

Volume (Avg)

75.55k (210.74k)

Day's Range

2.90-2.98

52Wk Range

2.55-7.00

Market Cap.

23.36M

Dividend Rate ( Yield )

-

Beta

1.20

Shares Outstanding

23.79M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
  • Management effectiveness
Industry Biotechnology
Highlights
Analyst Recommendation: Hold
    • Revenue

    • 19.00k

    • Net Income

    • -15.62M

    • Market Cap.

    • 23.36M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -356.35

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.20

    • Forward P/E

    • -0.92

    • Price/Sales

    • 3.28

    • Price/Book Value

    • -0.66

    • Price/Cash flow

    • -0.72

      • EBITDA

      • -15.12M

      • Return on Capital %

      • -124.00

      • Return on Equity %

      • -

      • Return on Assets %

      • -124.00

      • Book Value/Share

      • -4.45

      • Shares Outstanding

      • 23.79M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Hold
        • 1 Year Price Target

        • 0.15

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -3.17

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • -57.90

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • -45.21

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -12.84

            • 82.75

            • Pre-Tax Margin

            • -356.35

            • 39.38

            • Net Profit Margin

            • -356.35

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 0.83

              • 2.92

              • Quick Ratio

              • 0.68

              • 2.35

              • Interest Coverage

              • -1,976.75

              • 38.02

              • Leverage Ratio

              • -

              • 2.21

              • Book Value/Share

              • -4.45

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -0.88

                • 217.39

                • P/E Ratio 5-Year High

                • -28.02

                • 634.30

                • P/E Ratio 5-Year Low

                • -0.80

                • 124.82

                • Price/Sales Ratio

                • 3.13

                • 9.52

                • Price/Book Value

                • -0.63

                • 8.61

                • Price/Cash Flow Ratio

                • -0.72

                • 50.51

                • Key Metrics

                • Company

                  • Shares Short

                    as of -

                  • -

                  • Short Ratio

                    as of -

                  • -

                  • Short % of Float

                    as of -

                  • -

                  • Shares Short

                    prior month

                  • -

                  • Trailing Annual Dividend Yield

                  • -

                  • 5 Year Average Dividend Yield

                  • -

                  • Key Metrics

                  • Company

                    • Payout Ratio

                    • -

                    • Dividend Date

                    • -

                    • Ex-Dividend Date

                    • -

                    • Last Split Factor

                      new per old

                    • -

                    • Last Split Date

                    • -

                    • Key Metrics

                    • Company

                    • Industry

                      • Return on Equity %

                        (5-Year Average)

                      • -

                        (-)

                      • 37.63

                        (27.20)

                      • Return on Assets %

                        (5-Year Average)

                      • -124.00

                        (-)

                      • 17.22

                        (13.81)

                      • Return on Capital %

                        (5-Year Average)

                      • -

                        (-)

                      • 21.78

                        (17.31)

                      • Income/Employee

                      • -

                      • 117.08k

                      • Inventory Turnover

                      • 2.61

                      • 1.48

                      • Asset Turnover

                      • 0.35

                      • 0.55

                      Current Historical
                      Financials
                      • Income Statement
                      • Balance Sheet
                      • Cash Flow
                      Operating Income
                      -20.96M
                      Operating Margin
                      -110,336.84
                      Total Equity
                      -
                      Retained Earnings
                      -
                      Free Cashflow
                      -
                      Price/Cashflow
                      -0.72
                      Ownership

                      Institutional Ownership

                      -

                      Top 10 Institutions

                      125.36%

                      Mutual Fund Ownership

                      5.30%

                      Float

                      99.78%

                      5% / Insider Ownership

                      16.70%

                      Corporate insiders or major stockholders reporting trading activity in the stock.

                      Top Mutual Fund Owners

                      Top Institutional Owners

                      Mutual Fund Name

                      Institution Name

                      • Mutual Fund Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Vanguard Total Stock Mkt Idx

                      •  

                        306,015

                      • 210.31

                      • 3.82

                      • Vanguard Extended Market Index Fund

                      •  

                        68,494

                      • 101.77

                      • 0.86

                      • OneWorld Tactics

                      •  

                        25,000

                      • 0.00

                      • 0.03

                      • Vanguard Instl Total Stock Market Index

                      •  

                        20,679

                      • 0.00

                      • 0.26

                      • Fidelity Spartan® Extended Mkt Indx Fd

                      •  

                        10,915

                      • 0.00

                      • 0.14

                      • USAA Extended Market Index Fund

                      •  

                        4,450

                      • -0.04

                      • 0.06

                      • Fidelity Spartan® Total Market Idx Fund

                      •  

                        3,923

                      • 0.00

                      • 0.05

                      • Wilshire Micro-Cap ETF

                      •  

                        3,437

                      • 0.00

                      • 0.04

                      • The Vanguard - Total Stk Mkt Idx Trust. CF

                      •  

                        2,507

                      • 0.00

                      • 0.03

                      • Promozalia SICAV

                      •  

                        1,251

                      • 0.00

                      • 0.02

                      • Institution Name

                      • Shares Held

                      • % Change

                      • % Outstanding

                      • Eastern Capital LTD

                      •  

                        1,390,581

                      • +33.66%

                      • 17.38

                      • Sabby Management LLC

                      •  

                        1,100,000

                      • -85.00%

                      • 13.75

                      • BlackRock Fund Advisors

                      •  

                        420,567

                      • +26.19%

                      • 5.99

                      • Vanguard Group, Inc.

                      •  

                        130,616

                      • 0.00%

                      • 1.86

                      • JANE STREET GROUP, LLC

                      •  

                        44,245

                      • +47.78%

                      • 0.63

                      Company Profile

                      Sector

                      Healthcare

                      Industry

                      Biotechnology

                      Type

                      Slow Growth

                      Style

                      Small Core

                      Aastrom Biosciences Inc was incorporated on March 24, 1989 and is a regenerative medicine company engaged in the development cell therapies to repair or regenerate damaged or diseased tissues. The Company is developing patient-specif...moreic, expanded multicellular therapies for use in the treatment of severe, chronic ischemic cardiovascular diseases; Ixmyelocel-T a disease modifying therapy with multi-functional properties including tissue remodeling, immuno-modulation and the promotion of angiogenesis. The Companys proprietary cell-manufacturing technology enables the manufacture of multicellular therapies, expanded from an adult patients own bone marrow, to be delivered directly to damage tissues. Preclinical and clinical data suggest that ixmyelocel-T may be safe and effective in treating patients wit...moreh severe, chronic ischemic cardiovascular diseases such as critical limb ischemia or CLI, the severe form of peripheral arterial disease or PAD, and dilated cardiomyopathy or DCM, the cause of heart failure. 200 patients have been treated in clinical trials using ixmyelocel-T, and 400 patients safely treated since the Companys inception. During the fourth quarter of 2012, it launched a randomized, placebo-controlled, double-blinded Phase 2b ixCELL-DCM trial for patients with ischemic DCM. Ixmyelocel-T is a patient-specific, expanded multicellular therapy developed using the Companys proprietary, fully-closed, automated processing system. Ixmyelocel-T is a product derived from an adult patients own bone marrow but it is enhanced compared with the original bone marrow. The manufacture of its patient-specific, expanded multicellular therapies is done under current Good Manufacturing Practices and current Good Tissue Practices guidelines required by the U.S. Food and Drug Administration. The Companys therapy is produced at its cell manufacturing facility in the United States, located at its headquarters in Ann Arbor, Michigan. Its clinical development programs are engaged in addressing areas of unmet medical needs in severe, chronic ischemic cardiovascular diseases. The Company has rights to approximately 17 unexpired issued U.S. patents. Eleven of these patents are material patents that protect its cellular therapy. It owns 10 of the patents and one has been licensed from the University of Michigan. These patents present claims relating to the composition of its cellular therapy, methods to manufacture or administer the cellular therapy, and the bioreactor device or the Aastrom Replicell System that is used to make its product. The Companys competitors include multi-national medical device companies, pharmaceutical companies, biotechnology companies and stem cell companies operating in the fields of tissue engineering, regenerative medicine, cardiac, vascular, orthopedics and neural medicine. The Companys research and development activities and the manufacturing and marketing of its products are subject to the laws and regulations of governmental authorities in the United States and other countries in which its products will be marketed.lessless

                      Key People

                      Dominick Colangelo

                      CEO/Director/President/Chief Accounting Officer/Treasurer

                      Dr. Robert L. Zerbe,M.D.

                      Director/Chairman of the Board

                      Mr. Gerard J. Michel

                      CFO/Vice President, Divisional

                      Nelson M. Sims

                      Director

                      Alan L. Rubino

                      Director

                      • Aastrom Biosciences Inc

                      • 24 Frank Lloyd Wright Drive

                      • Ann Arbor, MI 48106

                      • USA.Map

                      • Phone: +1 800 556-0311

                      • Fax: +1 734 665-0485

                      • aastrom.com

                      Incorporated

                      1989

                      Employees

                      40

                      Send Feedback

                      We appreciate your input!

                      • I'm having trouble signing into my Microsoft account

                      • I’m having problems with the services stripe (Mail, Facebook, etc.)

                      • There is an issue with my weather information

                      • I see an error in the content

                      • Other

                      Please give an overall site rating: